10-Q: Foghorn Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Foghorn Therapeutics reported its second quarter 2024 financial results, highlighting a recent capital raise and ongoing clinical development programs.

Summary

• Foghorn Therapeutics, a clinical-stage biopharmaceutical company, released its financial results for the second quarter of 2024.
• The company reported a net loss of $23 million for the quarter and $48 million for the six months ended June 30, 2024.
• Collaboration revenue was $6.9 million for the quarter and $11.9 million for the six months, primarily from the Eli Lilly collaboration.
• Research and development expenses were $23.8 million for the quarter and $49.3 million for the six months, reflecting ongoing clinical and preclinical activities.
• The company completed a public offering in May 2024, raising net proceeds of $102.8 million.
• As of June 30, 2024, Foghorn had $285.2 million in cash, cash equivalents, and marketable securities.
• The company expects its current cash resources to fund operations for at least the next 12 months.
• Foghorn is advancing its clinical-stage drug candidate, FHD-286, and anticipates a Phase 1 study for FHD-909 with Eli Lilly later this year.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company has a strong cash position and is progressing its clinical programs, but it is still incurring significant losses and is dependent on external funding. The recent capital raise is a positive sign, but the company's long-term success is still uncertain.

Positives

• The company successfully raised $102.8 million through a public offering in May 2024.
• Foghorn has a strong cash position of $285.2 million, which is expected to fund operations for at least the next 12 months.
• The collaboration with Eli Lilly continues to generate revenue and advance key programs.
• The company is actively progressing its clinical programs, including FHD-286 and the planned study for FHD-909.
• The company has a proprietary Gene Traffic Control platform that is being used to develop new medicines.

Negatives

• The company reported a net loss of $23 million for the second quarter of 2024 and $48 million for the first six months of 2024.
• Research and development expenses remain high at $23.8 million for the quarter and $49.3 million for the six months.
• The company is still in the clinical stage and has not generated any revenue from product sales.
• The company is dependent on external funding to continue operations.

Risks

• The company is subject to risks common to clinical-stage biopharmaceutical companies, including dependence on key personnel and the need for additional financing.
• There is no assurance that research and development will be successful or that products will obtain regulatory approval.
• The company may not be able to obtain financing on acceptable terms, which could force delays or reductions in research and development programs.
• The company is exposed to general economic conditions, including recessionary conditions, interest rates, and supply chain constraints.
• Geopolitical instability and armed conflicts could impact the company's operations and supply chains.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its clinical programs and continues research and development activities. They anticipate that a Phase 1 dose escalation study will start later this year with FHD-909, a selective ATPase inhibitor of SMARCA2 (BRM).

Management Comments

• Management expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months.
• Management will continue to pursue plans to obtain sufficient funding in the future on terms acceptable to the company to fund continuing operations when needed or at all.

Industry Context

Foghorn is operating in the competitive biopharmaceutical industry, focusing on novel therapeutics targeting the chromatin regulatory system. The company's collaboration with Eli Lilly highlights the industry trend of partnerships between larger pharmaceutical companies and smaller biotech firms to develop innovative treatments. The focus on precision medicine and genetically determined dependencies is also a growing trend in the oncology space.

Comparison to Industry Standards

• Foghorn's cash burn rate is typical for a clinical-stage biotech company, but the company's cash runway of at least 12 months is relatively strong compared to some peers.
• The collaboration revenue from Eli Lilly is a significant source of funding, which is a common strategy for biotech companies to offset high R&D costs.
• The company's focus on the chromatin regulatory system is a unique approach, differentiating it from companies targeting more traditional pathways.
• Comparable companies in the oncology space include those developing targeted therapies and immunotherapies, such as Blueprint Medicines, Deciphera Pharmaceuticals, and Mirati Therapeutics, which also face high R&D costs and the need for significant capital raises.

Management Changes

Legal Proceedings

• The company is not currently a party to any material litigation or legal proceedings.

Related Party Transactions

• The company has a consulting agreement with a scientific founder who is also a shareholder.
• The company has a collaboration agreement and stock purchase agreement with Eli Lilly and Company, making them a 5% or greater shareholder.
• The company had an agreement with Danforth Advisors, LLC for strategic and financial consulting services, and a managing director at Danforth served as interim CFO.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and the success of its clinical programs.
• Employees are affected by the company's financial stability and its ability to continue research and development.
• Customers (potential patients) are impacted by the company's ability to develop and commercialize new therapies.
• Suppliers and creditors are impacted by the company's financial health and its ability to meet its obligations.

Next Steps

• The company will continue to advance the Phase 1 dose escalation study of FHD-286 in acute myeloid leukemia.
• The company anticipates starting a Phase 1 dose escalation study of FHD-909 with Eli Lilly later this year.
• The company will continue to identify and advance additional research programs and product candidates.
• The company will seek marketing approvals for any product candidates that successfully complete clinical trials.

Key Dates

Keywords

biopharmaceutical, oncology, clinical-stage, FHD-286, FHD-909, Gene Traffic Control, Eli Lilly, SMARCA2, chromatin regulatory system, capital raise